Publications
2002
Laustsen PG, Michael D, Crute BE, Cohen SE, Ueki K, Kulkarni RN, Keller SR, Lienhard GE, Kahn R. Lipoatrophic diabetes in Irs1-/-/Irs3-/- double knockout mice. Genes & development. 2002;16(24):3213–3222.
Mauvais-Jarvis F, Kulkarni RN, Kahn R. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clinical endocrinology. 2002;57(1):1–9.
Kulkarni RN, Okada T. Tissue-specific targeting of the insulin receptor gene. Endocrine. 2002;19(3):257–266.
Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA, Kahn R. $\beta$-cell–specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter $\beta$-cell mass. Nature genetics. 2002;31(1):111.
2001
Flier SN, Kulkarni RN, Kahn R. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proceedings of the National Academy of Sciences. 2001;98(13):7475–7480.
Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN, Kahn R, De Vargas LM, Berggren P-O. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic $\beta$ cells. Molecular cell. 2001;7(3):559–570.
2000
Kulkarni R, Wang Z, Wang R, Smith D, Ghatei M, . Glibenclamide but not other sulphonylureas stimulates release of neuropeptide Y from perifused rat islets and hamster insulinoma cells. Journal of endocrinology. 2000;165(2):509–518.
Mauvais-Jarvis F, Virkamaki A, Michael D, Winnay JN, Zisman A, Kulkarni RN, Kahn R. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes.. Diabetes. 2000;49(12):2126–2134.
Michael D, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Molecular cell. 2000;6(1):87–97.